These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4591152)

  • 1. A new sustained-release tablet formulation of procainamide.
    Fremstad D; Dahl S; Jacobsen S; Lunde PK; Nådland KJ; Marthinsen AA; Waaler T; Landmark KH
    Eur J Clin Pharmacol; 1973 Dec; 6(4):251-5. PubMed ID: 4591152
    [No Abstract]   [Full Text] [Related]  

  • 2. Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets.
    Arstila M; Katila M; Sundquist H; Anttila M; Pere E; Tikkanen R
    Acta Med Scand; 1974 Mar; 195(3):217-22. PubMed ID: 4595254
    [No Abstract]   [Full Text] [Related]  

  • 3. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma levels of procaine amide after administration of conventional and sustained-release tablets.
    Karlsson E
    Eur J Clin Pharmacol; 1973 Dec; 6(4):245-50. PubMed ID: 4591151
    [No Abstract]   [Full Text] [Related]  

  • 5. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
    Henningsen P; Laursen HB; Christiansen BD; Moller J
    Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
    [No Abstract]   [Full Text] [Related]  

  • 6. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: Time-dependent effect of oral procainamide in patients with exertional arrhythmias.
    Levy RH; Gey GO; Bruce RA
    J Pharm Sci; 1974 Dec; 63(12):1958-9. PubMed ID: 4449032
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic of procainamide in man.
    Koch-Weser J
    Ann N Y Acad Sci; 1971 Jul; 179():370-82. PubMed ID: 5285382
    [No Abstract]   [Full Text] [Related]  

  • 9. Procainamide in acute myocardial infarction: a study on two different tablet preparations of sustained release type.
    Ihlen H; Ditlefsen L
    Curr Ther Res Clin Exp; 1975 Nov; 18(5):720-6. PubMed ID: 812650
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutical and pharmacokinetic principles in the formulation of a sustained-release procainamide tablet.
    Dahl SG; Fremstad D; Jacobsen S; Kvaleid I; Landmark KH; Lunde PK; Marthinsen AA; Nådland KJ; Waaler T
    Pharm Acta Helv; 1976; 51(7-8):204-8. PubMed ID: 967912
    [No Abstract]   [Full Text] [Related]  

  • 11. Agranulocytosis due to new sustained-release procainamide.
    Berger BE; Hauser DJ
    Am Heart J; 1983 Jun; 105(6):1035-6. PubMed ID: 6858823
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of plasma levels in evaluation of procainamide dosage.
    Shaw TR; Kumana CR; Royds RB; Padgham CM; Hamer J
    Br Heart J; 1974 Mar; 36(3):265-70. PubMed ID: 4132893
    [No Abstract]   [Full Text] [Related]  

  • 13. Maintenance therapy with a new retard tablet preparation of procainamide.
    Hansteen V; Landmark KH; Fremstad D; Dahl SG; Jacobsen S; Marthinsen AA; Waaler T; Frislid K; Lunde PK
    Am Heart J; 1976 Jul; 92(1):47-56. PubMed ID: 785987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of the pharmacokinetics of procaine amide.
    Koch-Weser J
    Cardiovasc Clin; 1974; 6(2):63-75. PubMed ID: 4613464
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained release procainamide in patients with myocardial infarction.
    Birkhead J; Evans T; Mumford P; Martinez E; Jewitt D
    Br Heart J; 1976 Jan; 38(1):77-80. PubMed ID: 1252299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH; Rocci ML; Porrini KA; Greenspon AJ; Ferguson RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical use of procainamide.
    Miller RR; Greenblatt DJ
    Am J Hosp Pharm; 1974 Sep; 31(9):889-91. PubMed ID: 4607729
    [No Abstract]   [Full Text] [Related]  

  • 18. Conventional and sustained-release procainamide: update on pharmacology and clinical use.
    Anderson JL
    Clin Ther; 1985; 7(5):618-40. PubMed ID: 3902240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of sustained-release procainamide in treatment of cardiac arrhythmias.
    Michelson EL; McGeehin FC; Levin BK
    Angiology; 1988 Jul; 39(7 Pt 2):647-54. PubMed ID: 3044199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML; Babich MF; Klinke WP; Hui WK
    Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.